Noncanonical epitopes presented by Human Leucocyte Antigen class I (HLA-I) complexes to CD8+ T cells attracted the spotlight in the research of novel immunotherapies against cancer, infection and autoimmunity. Proteasomes, which are the main producers of HLA-I-bound antigenic peptides, can catalyze both peptide hydrolysis and peptide splicing. The prediction of proteasome-generated spliced peptides is an objective that still requires a reliable (and large) database of non-spliced and spliced peptides produced by these proteases. Here, we present an extended database of proteasome-generated spliced and non-spliced peptides, which was obtained by analyzing in vitro digestions of 80 unique synthetic polypeptide substrates, measured by differen...
Spliced peptides are short protein fragments spliced together in the proteasome by peptide bond form...
Within the tumor immunology community, the topic of proteasomal spliced peptides (PSP) has generated...
In the current era of T cell-based immunotherapies, it is crucial to understand which types of MHC-p...
Abstract Noncanonical epitopes presented by Human Leucocyte Antigen class I (HLA-I) complexes to CD8...
CD8+ cytolytic T lymphocytes are essential players of anti-tumor immune responses. On tumors, they r...
The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules t...
The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules t...
The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules t...
The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules t...
The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules t...
The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules t...
The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules t...
The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules t...
The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules t...
Spliced peptides are short protein fragments spliced together in the proteasome by peptide bond form...
Spliced peptides are short protein fragments spliced together in the proteasome by peptide bond form...
Within the tumor immunology community, the topic of proteasomal spliced peptides (PSP) has generated...
In the current era of T cell-based immunotherapies, it is crucial to understand which types of MHC-p...
Abstract Noncanonical epitopes presented by Human Leucocyte Antigen class I (HLA-I) complexes to CD8...
CD8+ cytolytic T lymphocytes are essential players of anti-tumor immune responses. On tumors, they r...
The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules t...
The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules t...
The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules t...
The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules t...
The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules t...
The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules t...
The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules t...
The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules t...
The proteasome generates the epitopes presented on human leukocyte antigen (HLA) class I molecules t...
Spliced peptides are short protein fragments spliced together in the proteasome by peptide bond form...
Spliced peptides are short protein fragments spliced together in the proteasome by peptide bond form...
Within the tumor immunology community, the topic of proteasomal spliced peptides (PSP) has generated...
In the current era of T cell-based immunotherapies, it is crucial to understand which types of MHC-p...